vTv Therapeutics Inc. (NASDAQ: VTVT) shares went skyward Tuesday. The company, a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes, today announced that it has entered into a purchase agreement for an $80 million private placement in public equity financing with leading healthcare institutional investors and the T1D Fund: A Breakthrough T1D Venture, LLC. The PIPE financing is subject to customary closing conditions and is expected to close on or around Wednesday of this week.
Investors in the financing include existing investors in the Company: a life sciences-focused institutional investor, Samsara BioCapital, L.P., and the T1D Fund. New investors include Trails Edge Capital Partners, and Invus.
TD Cowen and Evercore ISI are acting as lead placement agents for the PIPE financing.
Pursuant to the terms of the purchase agreement, the Company is selling to the investors units consisting of an aggregate of 682,018 shares of the Company’s Class A Common Stock and pre-funded warrants to purchase 4,561,714 shares of the Company’s Class A Common Stock, with accompanying warrants to purchase an aggregate of 5,243,732 shares of the Company’s Class A Common Stock.
VTVT shares spiked 76 cents, or 4.7%, to $17.00.
